[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Casa di Cura Dott. Pederzoli\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":318},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,48,75,104,131,157,184,210,234,264,293],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100633892","patients-with-pancreatic-tumor-use-of-an-app-to-monitor-progress-in-a-simple-and-intuitive-way-by-periodically-completing-targeted-questionnaires-and-providing-educational-and-informational-content-pancreasplus-100633892",false,"NCT07532590","Patients With Pancreatic Tumor: Use of an App to Monitor Progress in a Simple and Intuitive Way by Periodically Completing Targeted Questionnaires and Providing Educational and Informational Content (PancreasPlus).","A Prospective Study on the Use of an App (PancreasPlus) for Home Monitoring and Proactive Management of Patients With Pancreatic Cancer.","Inclusion Criteria:\n\n* Age ≥18; diagnosis of pancreatic cancer (histological\u002Fcytological)\n* Access to a smartphone or tablet and a data connection; basic digital literacy or a caregiver available,\n* Ability to understand and provide informed consent; understanding of the Italian language.\n\nExclusion Criteria:\n\n* Severe uncompensated cognitive impairment,\n* Social or logistical circumstances that prevent follow-up or access to\u002Fuse of the app,\n* Refusal or withdrawal of consent.","ALL","18 Years",{"count":19,"type":20},185,"ESTIMATED","INTERVENTIONAL",[23],"NA","Caring for people with pancreatic cancer requires good coordination between hospital care and care at home, with different healthcare professionals working closely together. Patients are also becoming more involved in managing their own care on a daily basis. However, this active involvement can be difficult if there is poor communication with healthcare teams, differences in skills or familiarity with digital tools, or systems that do not support patient participation.\n\nThe PancreasPlus app was developed to support patients and caregivers by providing reliable information, self-monitoring tools, and a communication channel with healthcare professionals. The study aims to assess the feasibility, patient engagement, and perceived quality of routine use of the app. It is hypothesized that its use will improve engagement, perceived quality, reduce anxiety and unplanned hospital visits, without introducing technological or privacy risks. The app supports information and data collection but does not replace clinical decision-making.\n\nObjectives\n\nPrimary objectives:\n\nAssess feasibility and patient engagement through questionnaire completion. Evaluate perceived service quality using the Client Satisfaction Questionnaire (CSQ-8).\n\nSecondary objectives:\n\nMonitor unplanned hospital visits and adherence to chemotherapy. Assess anxiety (HADS-A), nutritional status, and global quality of life (PROMIS Global).\n\nEvaluate usability and acceptability of the app (SUS, UTAUT2 short version).\n\nEndpoints Primary endpoints include questionnaire completion rates and perceived quality (CSQ-8 score). Secondary endpoints include unplanned hospital access, chemotherapy adherence, anxiety levels, nutritional status, quality of life, and app usability\u002Facceptability.\n\nMethods This is a prospective, interventional, multicenter study with consecutive enrollment of eligible patients. Each participant will be followed for 3 months, with most activities conducted remotely via the app.\n\nAt baseline (T0), patients receive study information, provide consent, undergo training, register in the app, and complete initial assessments (clinical, socio-demographic, PROMIS Global, HADS-A). At 12 weeks (W12), follow-up includes all outcome questionnaires and data on unplanned hospital visits.\n\nThe app includes features such as a personal diary (symptoms, weight, BMI, appointments), interactive questionnaires with tailored feedback, and educational content on nutrition, prevention, emotional support, and patient rights.\n\nPopulation Inclusion criteria: adults (≥18 years) with pancreatic cancer, access to a smartphone\u002Ftablet (or caregiver support), ability to consent, and understanding of Italian. Exclusion criteria include severe cognitive impairment, inability to use the app or complete follow-up, or withdrawal of consent.\n\nSample Size and Analysis A total of 185 patients will be enrolled (accounting for 10% dropout), based on an expected 70% engagement rate. Analyses will be conducted on both intention-to-observe and per-protocol populations. Engagement will be analyzed as questionnaire completion rates, while other outcomes will be analyzed using appropriate statistical models (e.g., logistic regression, ANCOVA, descriptive statistics). An interim analysis at 50% enrollment is planned to address potential low engagement.",[26,27,28,29,30,31],"Ductal Adenocarcinoma of Pancreas","Pancreatectomy","Caregiver","Nutritional Evaluation","Post Surgery Patients","Pain Management",[33,34],"App","Quality of life","RECRUITING","2026-05-06",{"date":38,"type":39},"2026-05-11","ACTUAL",{"date":41,"type":39},"2026-02-26",{"date":43,"type":20},"2027-04",{"name":45,"class":46},"Casa di Cura Dott. Pederzoli","OTHER",2,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100626907","evaluate-the-implementation-of-using-indocyanine-green-for-sentinel-lymph-node-mapping-in-breast-cancer-patients-100626907","NCT07441733","Evaluate the Implementation of Using Indocyanine Green for Sentinel Lymph Node Mapping in Breast Cancer Patients","INFLUENCE II - a Pilot Study for Implementation Identification of Sentinel Lymph Nodes in Breast Cancer Patients Through Non-invasively FLUorEsceNt Imaging Using indoCyaninE Green: a Pilot Study for Implementation","INFLUENCE II","Inclusion Criteria:\n\n* Clinically node-negative, DCIS or invasive stage T1-T3 breast cancer confirmed by biopsy\n* Preoperative axillary ultrasound to confirm clinical node-negative status\n* Indication for breast cancer surgery with SLNB via axillar incision\n* Written informed consent according to national regulations\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years old.\n* Indication for breast cancer surgery with SLNB via mastectomy incision\n* Known allergy for ICG, intravenous contrast or iodine\n* History of axillary lymph node dissection\n* Pregnancy or breast-feeding\n* Psychological, familial, sociological or geographical factors that could potentially hamper compliance with the study protocol","FEMALE",{"count":58,"type":20},40,[23],"This single-institution pilot study uses a pre- and post-implementation design to evaluate the implementation of ICG fluorescent imaging for sentinel lymph node biopsy (SLNB) in an Italian hospital.",[62],"Breast Cancer",[64,65,66,67],"breast cancer","lymph node","99mTc","ICG",{"date":38,"type":39},{"date":70,"type":39},"2024-11-07",{"date":72,"type":20},"2026-10",{"name":45,"class":46},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100635796","assessment-of-sexual-well-being-in-patients-with-gynecologic-cancer-and-their-partners-the-oncosex-study-100635796","NCT07557342","Assessment of Sexual Well-being in Patients With Gynecologic Cancer and Their Partners: the ONCOSEX Study","ONCOSEX","Inclusion Criteria:\n\n* Patients diagnosed with gynecological cancer: malignant ovarian tumor, ovarian tumor of uncertain behavior, cervical cancer, endometrial cancer, uterine sarcoma, vulvar cancer, vaginal cancer\n* Sexually active\n* Women who have a partner\n* Aged between 18 and 75\n* Women of any sexual orientation\n* Understanding and knowledge of the Italian language\n* Signing of the informed consent form\n* Signing of the informed consent form by the partner\n\nExclusion Criteria:\n\n* Benign gynecological conditions\n* Age \\\u003C 18 or \\> 75\n* Virgins or women who are no longer sexually active\n* Women with psychiatric or neurological disorders\n* Women or partners who have already undergone sexual counseling or sex therapy\n* Women who are unable to sign the informed consent form for the study","75 Years",{"count":84,"type":20},200,"OBSERVATIONAL","Study type and design This is an observational, exploratory, prospective, longitudinal (cohort), multicenter, non-profit study. Its purpose is to observe changes in sexual function over time without modifying standard clinical care pathways.\n\nBackground and rationale Sexual dysfunctions and the psychological impact of gynecological cancers are often underestimated in clinical practice, despite the World Health Organization recognizing sexual health as a fundamental right. Cultural, personal, and educational barriers frequently hinder an open and systematic discussion of sexual health.\n\nAvailable literature highlights a significant deterioration in sexual quality of life and couple relationships among these patients; however, clear guidance on validated assessment tools and structured sexual counseling pathways is still lacking.\n\nStudy objectives\n\nPrimary objective: to evaluate whether and how sexual function questionnaire scores in patients and their partners change over time at different assessment time points.\n\nSecondary objective: to identify the proportion of patients and partners who would perceive sexual counseling as useful, as well as the preferred timing for such support.\n\nEndpoints\n\nPrimary endpoint: variation in Female Sexual Function Index (FSFI) scores in female patients and International Index of Erectile Function (IIEF-15) scores in male partners between assessment time points (T0-T1, T1-T2, T0-T2).\n\nSecondary endpoint: perceived usefulness of sexual counseling support and preferred timing, based on questionnaire responses.\n\nProcedures and assessment timeline Patients are enrolled at the time of diagnosis communication (T0). The same questionnaire is administered again six months after the start of treatment (T1) and twelve months after completion of therapy or surgery (T2). Participation requires written informed consent, and all data are collected in a pseudo-anonymized format. Partners are enrolled and assessed at the same time points.\n\nAssessment tools\n\nPatients: the validated Female Sexual Function Index (FSFI) questionnaire, plus an additional structured section exploring sexual experience, satisfaction, and difficulties.\n\nPartners: the IIEF-15 questionnaire for male partners; for female partners, the same instruments used for patients are administered.\n\nCollected variables Sociodemographic and clinical data, lifestyle habits, sleep quality, marital status, parity, ongoing or previous therapies, and FSFI and IIEF-15 questionnaire scores.\n\nSample size A total of 200 patients and 200 corresponding partners are expected to be enrolled.\n\nStatistical analysis Data will be analyzed descriptively and longitudinally across the three time points. The primary analysis will use linear mixed-effects models for repeated measures, including random effects for subjects and fixed effects for time and relevant clinical covariates. Predefined subgroup analyses are planned. Statistical significance is set at p \\\u003C 0.05.",[88,89],"Sexual Wellness","Gynecologic Cancers",[91,92,93,94],"gynecologic cancers","sexuality","partner","cancer survivors","2026-04-22",{"date":97,"type":39},"2026-04-29",{"date":99,"type":20},"2026-04",{"date":101,"type":20},"2028-04",{"name":45,"class":46},6,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":113,"conditions":114,"keywords":118,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":128,"leadSponsor":130,"locationsCount":74},"100632723","study-of-collection-and-analysis-of-clinical-anamnestic-functional-biological-data-through-the-support-of-artificial-intelligence-to-evaluate-the-possibility-of-defining-a-digital-twin-of-the-lung-luce-100632723","NCT07517393","Study of Collection and Analysis of Clinical, Anamnestic, Functional, Biological Data Through the Support of Artificial Intelligence to Evaluate the Possibility of Defining a Digital Twin of the Lung (LUCE)","LUCE: LUng Cancer (r)Evolution","Inclusion Criteria:\n\n* Men or women aged ≥ 18 years who will perform a smdc photon count chest CT scan\n* written informed consent.\n\nExclusion Criteria:\n\n* Lack of information regarding anamnestic data\n* any reason why the investigator deems the patient unenrollable in the practice.",{"count":112,"type":20},1000,"This research study aims to retrospectively and prospectively analyze the clinical, anamnestic, functional, biological data of patients who have performed or will perform non-contrast chest photon count CT.\n\nThe use of contrast medium is evaluated by the physician. Main objective The study aims to understand how many people who undergo non-contrast photon-counting chest CT have: lung nodules, chest tumors, and other non-cancerous lung diseases.\n\nSecondary objectives\n\n* Analyze the data with the help of artificial intelligence to create a \"digital twin\" of the lung, that is, a virtual copy of the lung that allows you to study and simulate the behavior of the lung for research and analysis purposes, without directly intervening on the patient.\n* Follow any suspicious lung changes over time to understand how they change and whether they are linked to clinical, biological, or laboratory parameters.\n\nThe enrollment phase will last 12 months and will begin with the approval of the study. At this stage, clinical data already present in the patient's medical record and data relating to the photon count CT examination will be collected. After the enrollment phase, the patient will be observed for a further total duration of 10 years: in particular, a follow-up visit will be arranged at two, five and ten years. More specifically, if there are no radiological elements that require scheduling a visit to the center, the patient will be contacted by telephone for a telematic update of the data. If, however, pulmonary alterations are identified during the study, the patient will be referred to the Reference Operating Unit, as per clinical practice, to continue with the most appropriate personalized diagnostic-therapeutic process. In these cases, the patient will be contacted by telephone and an appointment with the institution will be suggested.",[115,116,117],"Thoracic Neoplasm","Pulmonary Nodules","Non-oncological Pulmonary Pathologies",[119,120,121,122,123],"Lung","Artificial Intelligence","observational","Photon Counting Computed Tomography","thoracic malignancies","2026-04-01",{"date":126,"type":39},"2026-04-08",{"date":99,"type":20},{"date":129,"type":20},"2036-03",{"name":45,"class":46},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":74},"100626109","evaluation-of-dietary-knowledge-and-the-habit-of-using-the-mediterranean-diet-in-patients-with-diabetes-100626109","NCT07431359","Evaluation of Dietary Knowledge and the Habit of Using the Mediterranean Diet in Patients With Diabetes","RELATIONSHIP Between ALimentary Knowledge and Adherence to the Mediterranean Diet in Patients With DIABete Mellito Type 2 Attending an Outpatient Service (REALDIAB)","REALDIAB","Inclusion Criteria:\n\n* T2DM in nutritional and\u002For pharmacological euglycemic treatment (metformin, gliptins, gliflozines, incretin mimetics, pioglitazone)\n* Signing of informed consent\n\nExclusion Criteria:\n\n* Patient with Diabetes Mellitus type 1\n* Patients with insulin T2DM treated","80 Years",{"count":141,"type":20},500,"The main aim of this study is to evaluate nutritional knowledge and adherence to the Mediterranean diet through the administration of questionnaires in patients with type 2 Diabetes Mellitus belonging to Outpatient Diabetology Service of the Hospital.",[144],"Type 2 Diabetes",[146,147,148],"Diabetes","mediterranean diet","nutrition","2026-02-23",{"date":151,"type":39},"2026-02-24",{"date":153,"type":39},"2025-05-22",{"date":155,"type":20},"2026-05-19",{"name":45,"class":46},{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":56,"minAge":17,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":183},"100625839","observational-study-on-the-use-of-ultrasound-to-recognize-superficial-endometriosis-in-a-specific-area-of-the-pelvis-the-uterosacral-ligaments-100625839","NCT07427849","Observational Study on the Use of Ultrasound to Recognize Superficial Endometriosis in a Specific Area of the Pelvis (the Uterosacral Ligaments)","Ultrasound Diagnosis of Superficial Endometriosis of LUS (Uterosacral Ligaments): Definition of a Laparoscopically Validated Ultrasound Cut-off.","LUS","Inclusion Criteria:\n\n* patients who need to undergo gynecological surgery with a laparoscopic approach for benign pathology (endometriosis, uterine fibroids, adenomyosis, chronic pelvic pain, benign ovarian cysts) or non-advanced malignant pathology (stage I endometrium and cervix, stage I and II ovary).\n* patients who performed a level II gynecological ultrasound with an experienced operator in the preoperative pathway.\n* technical possibility of performing a transvaginal ultrasound and the patient's willingness to undergo such an investigation.\n* patients of childbearing age (18 - 50 years).\n* Signing of informed consent.\n\nExclusion Criteria:\n\n* presence of endometriosis deeply infiltrating the posterior compartment. This may interfere with the interpretation of uterosacral ligament (LUS) thickness as a specific marker of superficial endometriosis\n* technical impossibility of performing a transvaginal ultrasound (patient virgo, patient refusal).\n* incomplete ultrasound evaluation of the uterosacral ligaments for anatomical reasons or for the presence of endometriosis nodules from other sites with partial involvement of the LUS (uterosacral ligament).\n* advanced malignant disease (\\>Stage I for endometrium and cervix, \\> Stage II for ovary)\n* pelvic organ prolapse\n* PID or other pelvic inflammatory diseases\n* medical emergencies (ovarian torsion, hemoperitoneum)\n* postmenopausal patients\n* previous pelvic surgery","50 Years",{"count":167,"type":20},64,"An observational, prospective, multicenter study conducted on patients of childbearing age undergoing laparoscopic surgery for early-stage benign or malignant gynecological disease. The study does not include changes to the standard care pathway.",[170],"Endometriosis (Diagnosis)",[172,173,174,175],"ultrasound","gynecology","laparoscopic surgery","uterosacral ligaments",{"date":177,"type":39},"2026-02-25",{"date":179,"type":39},"2026-02-17",{"date":181,"type":20},"2026-08",{"name":45,"class":46},4,{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":85,"phases":4,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":74},"100626619","collection-of-demographic-clinical-and-instrumental-data-of-patients-with-peripheral-neuropathy-including-neurological-examination-data-peripheral-nerve-conduction-analysis-and-nerve-electromyography-and-ultrasound-100626619","NCT07437989","Collection of Demographic, Clinical, and Instrumental Data of Patients With Peripheral Neuropathy Including Neurological Examination Data, Peripheral Nerve Conduction Analysis, and Nerve Electromyography and Ultrasound).","An Observational Prospective Study on Patients With Peripheral Neuropathies Explored With a Combined Clinical, Neurophysiological and Nerve Ultrasound Approach- REG-NP","REG-NP","Inclusion Criteria:\n\n1. Adult patients (age ≧ 18 years old) able to give consent\n2. Diagnosis of peripheral nerve disorder\n\nExclusion Criteria:\n\n1\\. The patient is unable to consent for him\u002Fherself",{"count":193,"type":20},4000,"The study involves recording personal, clinical, and instrumental information. The acquisition of the above-mentioned personal and clinical information will be carried out in conjunction with the usual follow-up visits scheduled as part of normal clinical practice. At the end of the study, a statistical analysis of the data will be carried out.",[196],"Neuropathy",[172,198,199,200,201],"peripheral nervous system","Neurological","Electrodiagnostic","Neuromuscolar ultrasound","2026-02-20",{"date":204,"type":39},"2026-02-27",{"date":206,"type":39},"2025-02-23",{"date":208,"type":20},"2035-02",{"name":45,"class":46},{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":216,"eligibilityCriteria":217,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":21,"phases":220,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":74},"100626620","analysis-of-effects-of-high-intensity-physical-exercise-in-subjects-with-dialyzed-chronic-kidney-disease-and-in-conservative-treatment-100626620","NCT07438002","Analysis of Effects of High-intensity Physical Exercise in Subjects With Dialyzed Chronic Kidney Disease and in Conservative Treatment","Effect of Exercise in Patients With Chronic Kidney Disease: TONE Trial","TONE","Inclusion Criteria:\n\n* Signature of the informed consent\n* Patients with CKD stage 1 to 5 under conservative treatment\n* Patients undergoing chronic hemodialysis for at least 3 months\n* Age ≥ 18\n\nExclusion Criteria:\n\n* Severe cardiovascular disease (NYHA class IV or hypertension class III)\n* TIA or myocardial ischemia within the last three months\n* Anatomical limitations\n* Health conditions detected during the stress test (CPET)",{"count":219,"type":20},50,[23],"This study aims to analyze the effects of physical activity in patients with chronic kidney disease undergoing dialysis or conservative treatment. Patients will be randomized into two groups: combined exercise (high-intensity aerobic resistance + strength training) and control group",[223],"Chronic Kidney Disease",[225,226,227],"Nephrology","exercise","physical activity",{"date":204,"type":39},{"date":230,"type":39},"2025-09-02",{"date":232,"type":20},"2026-09",{"name":45,"class":46},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":11,"sex":16,"minAge":242,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":21,"phases":246,"briefSummary":247,"conditions":248,"keywords":250,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":74},"100625945","evaluation-through-innovative-examinations-of-intestinal-dysbiosis-status-in-patients-diagnosed-with-cardiovascular-diseases-and-evaluation-of-the-efficacy-of-natural-and-probiotic-extracts-in-the-non-pharmacological-approach-to-improving-intestinal-dysbiosis-status-100625945","NCT07429227","Evaluation Through Innovative Examinations of Intestinal Dysbiosis Status in Patients Diagnosed With Cardiovascular Diseases and Evaluation of the Efficacy of Natural and Probiotic Extracts in the Non-pharmacological Approach to Improving Intestinal Dysbiosis Status.","Metabolomic and Cellular Inflammaging Investigation Study of Patients With Acute Coronary Syndrome (ACS)","DISBIO","Inclusion Criteria:\n\n* 1\\. Signing of informed consent\n* 2\\. Diagnosis of Acute Coronary Syndrome (ACS)\n* 3\\. Age 30-70\n\nExclusion Criteria:\n\n1. Use in the three months preceding the signing of the informed consent of:\n\n   i) Lipid-lowering drugs containing statins, ezetimibe, fibrates ii) Lipid-lowering nutraceuticals containing monacolin K iii) Monoclonal antibodies that inhibit PCSK9 (proprotein convertase subtilisin\u002Fkexin type 9) such as Evolocumab and Alirocumab\n2. Diagnosis of conditions such as HIV, cancer and diabetes I and II Furthermore, if a female patient becomes pregnant during the trial, this will be one of the reasons for early exit from the study.","30 Years","70 Years",{"count":245,"type":20},15,[23],"The prospective experimental study aims to take an instantaneous photograph of the subject at time T0 and after 24 hours of intestinal permeability and dysbiosis indices in patients with acute coronary syndromes (ACS) which include unstable coronary artery disease (unstable angina) and acute myocardial infarction (AMI). The aim is to verify whether essential oils in particular formulations with high bioavailability are able to re-establish intestinal eubiosis after 2 months, confirmed by tests laboratory specifics such as metabolomics.",[249],"Acute Coronary Syndromes (ACS)",[251,252,253,254,255,256,257],"intestinal permeability","unstable coronary artery disease","acute myocardial infarction","metabolomic","essential oils","dietary supplement","dysbiosis",{"date":151,"type":39},{"date":260,"type":20},"2026-03",{"date":262,"type":20},"2027-03",{"name":45,"class":46},{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":21,"phases":274,"briefSummary":275,"conditions":276,"keywords":283,"overallStatus":284,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":74},"100625397","pan-clo-bu-pancreas-clostridium-butyricum-100625397","NCT07422103","PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum)","Supplementation With Clostridium Butyricum CBM588 in Patients Undergoing Pancreaticoduodenectomy for Periampullary Neoplasms: A Prospective Randomized Double-Blind Study","PAN-CLO-BU","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent\n* Patients undergoing pancreaticoduodenectomy\n* Candidates for upfront surgery without previous neoadjuvant chemotherapy or radiotherapy\n* Patients with benign or malignant periampullary neoplasms\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Previous or current use of Clostridium butyricum CBM588\n* Lactose intolerance\n* Neoadjuvant chemotherapy or radiotherapy",{"count":273,"type":20},158,[23],"This is a prospective, randomized, double-blind, single-center clinical trial designed to evaluate the effects of Clostridium butyricum CBM588 supplementation on postoperative diarrhea, gastrointestinal symptoms, and quality of life in patients undergoing pancreaticoduodenectomy for periampullary neoplasms. Oncological outcomes, including disease-free survival and overall survival, will be monitored as secondary endpoints during follow-up.",[277,278,279,280,281,282],"Pancreatic Cancer","Pancreatic Diseases","Gastrointestinal Symptoms","Clostridium Butyricum Miyairi","Pancreatoduodenectomy","CBM588",[277,278,279,280],"NOT_YET_RECRUITING","2026-02-12",{"date":287,"type":39},"2026-02-19",{"date":289,"type":20},"2026-03-15",{"date":291,"type":20},"2030-11-30",{"name":45,"class":46},{"id":294,"slug":295,"hasResults":11,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":21,"phases":304,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":74},"100552117","first-day-versus-early-drain-removal-following-pd-a-randomized-controlled-trial-100552117","NCT06468917","First-day Versus Early Drain Removal Following PD: a Randomized Controlled Trial","First-day Versus Early Drain Removal Following Pancreaticoduodenectomy: a Randomized Controlled Trial","FIDEL","Inclusion Criteria:\n\n* Patients (age ≥ 18 or \\\u003C 85 years) undergoing elective pancreaticoduodenectomy providing informed consent.\n* Intraoperative low to moderate risk for POPF (ISGPS class A-B-C)\n* POD 1 DFA \\\u003C 300U\u002FL\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>85\n* Patients with high risk of developing pancreatic fistula (ISGPS class D)\n* Intraoperative positioning of external or internal pancreatic stent\n* POD 1 DFA ≥300\n* Sinister appearance of drain effluent (defined as dark brown to clear \"spring water\" fluid that looks like pancreatic juice contaminated) as mentioned in literature3-22\n* Early post-pancreatectomy hemorrhage\n* Intraoperative conditions different from POPF risk, requiring prolonged intrabdominal drains\n* Previous bilio\u002Fpancreatic surgery\n* Allergy to drain materials\n* Significant coagulation disorders\n* Patients unable to provide informed consent.\n* Clinical suspect of another surgery-related fistula different than POPF","85 Years",{"count":303,"type":20},224,[23],"Pancreatic surgery is a complex discipline with a high risk of post-operative morbidity such as pancreatic fistula (POPF) with variable impact on clinical outcome. Controversies on ID placement have emerged from both randomized and non-randomized clinical studies investigating its possible role in increasing POPF and postoperative morbidity. The optimal timing for drain removal after PD is still a subject of debate: most studies have shown that outcomes are best when ID are removed in postoperative day (POD) 3 when POPF is excluded.\n\nAIM we aim to compare postoperative surgical outcomes after PD in patients with low\u002Fmedium risk for POPF (ISGPS risk class A-B-C), who undergo POD1 drains removal versus POD3 removal.\n\nPrimary aim: 1) grade B\u002FC POPF; 2) post-pancreatectomy hemorrhage (PPH). Secondary aims: occurrence of fluid collection, sepsis, SSI, need for reintervention, length of stay, CD\\>3, 90 days mortality, re-admission.\n\nStudy Design:\n\nThis is a randomized, controlled, open-label study. All patients will be randomized on POD1, using computer-generated randomization codes.\n\nGroup A: Drain removal on POD 1 (in case of POD 1 DFA\\\u003C 300 U\u002FL) Group B: Drain removal on POD 3 (in case of POD 1 DFA\\\u003C 300 U\u002FL)",[307],"Pancreas Fistula Abdominal Drains",[309],"pancreatic fistula pancreaticoduodenectomy drain fluid amylase","2024-06-20",{"date":312,"type":39},"2024-06-21",{"date":314,"type":39},"2024-06-01",{"date":316,"type":20},"2026-03-30",{"name":45,"class":46},""]